Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocetinostat + Ipilimumab + Nivolumab in Advanced Melanoma
NCT03565406Phase 1Terminated
- Sponsor
- NYU Langone Health
- Start
- Apr 2018
- Primary completion
- Jan 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mocetinostat in melanoma, sponsored by NYU Langone Health. Primary endpoint: Number of Dose Limiting Toxicities at 60 Months. Started Apr 2018; status: terminated.
02
Drugs
mocetinostat
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03565406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565406.